Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy - Scientific Reports
Source : https://www.nature.com/articles/s41598-023-32736-9
Patients with primary intestinal follicular lymphoma are often followed-up without a specific treatment, and this approach is called the "watch-and-wait approach." However, the long-term outcomes of this patient group have...
Conclusion: An indolent long-term clinical course was confirmed in the patients with primary intestinal follicular lymphoma. The watch-and-wait strategy is a reasonable approach for the initial management of these patients.
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36994552/
While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular...
Conclusions/Relevance: These data expand the knowledge on the genomics behind the heterogeneous FL population and, upon replication in larger cohorts, could contribute to risk stratification and the development of targeted therapies.
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
Research Article | Tycel J. Phillips, David A Bond, Radhika Takiar, Karson J. Kump, Malathi Kandarpa, philip boonstra, Tera Lynn Mayer, Victoria R Nachar, Ryan A Wilcox, Shannon Ann Carty,...
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
A Comprehensive Study of the Immunophenotype and its Clinicopathological Significance in Adult T-cell Leukemia/Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36997002/
Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell tumor caused by human T-lymphotropic virus type 1 (HTLV-1). The typical ATLL immunophenotypes are described in the 2017 World Health Organization Classification...
Conclusions/Relevance: The results of this study illustrate the diversity of ATLL phenotypes. In T-cell tumors occurring in HTLV-1 carriers, the possibility of ATLL should not be eliminated even when the tumor exhibits an atypical phenotype, and the confirmation of HTLV-1 in the tissue is recommended.
Pirtobrutinib: First Approval - Drugs
Source : https://link.springer.com/article/10.1007/s40265-023-01860-1
Pirtobrutinib (JaypircaTM), a highly selective, non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, is being developed by Eli Lilly and Company (Lilly) for the treatment of B-cell leukemias and lymphomas. In...
Relevance: In January 2023, pirtobrutinib was approved in the USA under the Accelerated Approval pathway for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response...